Company Profiles

driven by the PitchBook Platform

Akriveia Therapeutics

Akriveia Therapeutics
2016 FOUNDED
PRIVATE STATUS
Series A LATEST DEAL TYPE
$7.5M LATEST DEAL AMOUNT
$7.5M TOTAL AMOUNT RAISED
1 INVESTORS
Description

Provider of immunotherapy treatment for cancer. The company provides a platform designed to address issues with immunotherapies by restricting the action of the therapeutic agent to just the site of the cancer.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Primary Office
23 Southern Hills Drive
Skillman, NJ 08558
United States

+1 (609) 560-0927
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Akriveia Therapeutics’s full profile, request a free trial.

Akriveia Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 12-Oct-2016 $7.5M $7.5M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Akriveia Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
F-Prime Capital Partners Venture Capital Minority 000 0000 000000 0

You’re viewing 1 of 1 investors.

Akriveia Therapeutics Executive Team (5)

Name Title Board
Seat
Contact
Info
Simon Tomlinson Ph.D Chief Executive Officer and Board Member
C. Glenn Begley Ph.D Chief Scientific Officer
John Williams Ph.D Co-Founder and Member of Scientific Advisory Board
Ulrich Rodeck Ph.D Co-Founder and Member of Scientific Advisory Board
Margret Karow Ph.D Vice President, Drug Discovery and Preclinical Development

You’re viewing 5 of 5 executives.

Akriveia Therapeutics Board Members (4)

Name Representing Role Since Contact
Info
Benjamin Auspitz Akriveia Therapeutics Board Member 000 0000
Jessica Alston Ph.D F-Prime Capital Partners Board Observer 000 0000
Simon Tomlinson Ph.D Akriveia Therapeutics Chief Executive Officer and Board Member 000 0000
Tiffany Yu F-Prime Capital Partners Board Observer 000 0000

You’re viewing 4 of 4 board members.